Duphalac lactulose dosage

Triamterene hydrochlorothiazide tabs, 37.5 25 Maxzide-25 ; triamterene hydrochlorothiazide tabs, 75 50 Maxzide ; quinidine sulfate sotalol Betapace ; clonidine Catapres ; digoxin tabs Lanoxin ; doxazosin Cardura ; guanfacine Tenex ; methyldopa RESERPINE terazosin Hytrin ; cyproheptadine promethazine syrup, tabs promethazine supp chlorpheniramine pseudoephedrine codeine soln, 2 30 10 per 5 mL codeine guaifenesin soln, 10 100 per 5 mL Tussi-Organidin ; codeine guaifenesin syrup, 10 100 per 5 mL codeine guaifenesin tabs, 10 300 Brontex ; hydrocodone guaifenesin syrup, 2.5 200 per 5 mL Pneumotussin ; hydrocodone guaifenesin syrup, 5 100 per 5 mL Hycotuss ; pseudoephedrine guaifenesin ext-release caps, 60 300; ext-release tabs, 45 600, 60 pseudoephedrine guaifenesin ext-release tabs, 120 600 Zephrex LA ; albuterol inhaler Proventil ; albuterol sulfate syrup, tabs lactulose PEG electrolytes for soln Colyte ; PEG electrolytes for soln Nulytely ; cimetidine Tagamet ; dicyclomine Bentyl ; famotidine Pepcid ; hyoscyamine tabs Levsin ; hyoscyamine ext-release caps Levsinex ; hyoscyamine ext-release tabs Levbid ; ranitidine Zantac ; trimethobenzamide caps Tigan ; trimethobenzamide supp lactulose encephalopathy metoclopramide Reglan ; sulfasalazine Azulfidine ; nitrofurantoin monohydrate macrocrystals Macrobid ; oxybutynin Ditropan ; amino acid urea crm Amino-Cerv ; alprazolam Xanax ; buspirone Buspar ; diazepam inj Valium ; DIAZEPAM oral soln diazepam tabs Valium ; hydroxyzine pamoate Vistaril ; lorazepam Ativan ; amitriptyline.

Tion was stopped by adding I mLof ice-cold FCS or HSand the flasks were scraped with a cell scraper Greiner, Alphen a d Rijn, The Netherlands ; to include strongly adherent cells. A single-cell suspension was made by sieving the cell suspension through a 100pm nylonfilter. The cell suspension was taken up in IMDMand several concentrations of the suspension were plated in a semisolid CFC assay. CAFC assay. Confluent stromal layers of FBMD-I cells in flatbottom 96-well plates were overlaid with LP in a limiting dilution set-up.Inputvaluesrangedbetween 50, 000 and 24 NC perwell. Twelve dilutions twofold apart were used for each sample, with 15 replicatewellsper dilution. The cells werecultured in thesame medium and under the same conditions as the LTCs in flasks. To diminish the excessive superficial cell productionof LPs and consequently increase the visibility of the cobblestone areas, an HC concentration of IO-' mol L insteadof IO"' mol L wasused in the CAFC culture medium. The percentage of wells with at least one phase-dark hematopoieticclone of at least five cells ie, cobblestone area ; beneath the stromal layer was determined weekly for 6 weeks and CAFC frequencies were calculated using Poisson statistics as described Data analysis. Datawereanalyzedusing Slidewrite Plus for DOS-Version 6.0 Advanced Graphics Software, Carlsbad, CA ; . To characterize the data, curve fits were performed using least-squares a regression fit. Correlation coefficients for thecurve fit R ; were calculated. Statistical analysis was performed using GraphPad lnstat Graphpad Software, San Diego, CA ; . The Spearman's rank correlation coefficient rs ; was determined to quantitate the degree of linear association between two variables. A two-sided P value was calcucoeflated testing thenull hypothesis that the population correlation ficient equals 0. The means of two populations were compared using the Student's t-test. The two-sided P value was determined testing the null hypothesis that the two population means are equal. RESULTS.

Since 1991, all US nursing homes have been required to use a uniform, comprehensive assessment tool known as the Resident Assessment Instrument RAI ; with its Minimum Data Set MDS ; , 30 establishing a national, long-term care database. The present study used data from the Health Care Financing Administration's Multi-State, Case-Mix and Quality Demonstration Project involving all 1492 Medicare- and Medicaid-certified nursing homes in Kansas, Maine, Mississippi, New York, and South Dakota. We have merged 3 databases: 1 ; a computerized, longitudinal MDS data set on nearly 300 000 patients residing in, or admitted to, a nursing home in any of the 5 states during the period from January 1, 1992, through December 31, 1994; 2 ; a longitudinal file containing data on all drugs received by each patient; and 3 ; the Medicare enrollment files and Medicare Provider Analysis and Review database, which contains information on all persons covered by Medicare Part A. The resulting database Systematic Assessment of Geriatric Drug Use via Epidemiology [SAGE] ; has been described in detail elsewhere, 31-33 and it is briefly summarized herein. SAGE DATABASE The MDS includes sociodemographic information, numerous clinical items ranging from the degree of physical dependence to cognitive functioning, and all active clinical diagnoses.30, 31 The MDS also includes an extensive array of signs, symptoms, syndromes, treatments, and indicators that describe each resident's behavior and mood.30, 31 A variety of multi-item, summary scales are embedded in the MDS to examine the performance on Activities of Daily Living, cognition, mood status, behavioral problems, social engagement, communication, mobility, and urinary continence.32, 33 In addition to MDS data, staff recorded up to 18 different drugs received by each resident in the 7 days preceding the assessment. Information on the resident's drug therapy included brand or generic name, dosage, route and frequency of administration, and whether it was given on a standing or as-needed order.32 Drugs were coded according to the National Drug Code system. We used the Master Drug Data Base MediSpan Inc, Indianapolis, Ind ; to translate National Drug Codes into therapeutic classes and subclasses.33 POPULATION SAMPLE From an initial population of 296 379 unique individuals January 1, 1992, through December 31, 1994 ; , we.

Preferential warrant dividend increased by 3, 820 from , 666 in 2002 to 2, 486 in 2003. On June 2, 2003, we reduced the exercise price of 796, 331 outstanding warrants held by a shareholder to .00 per share. As a result, we recorded a preferential warrant dividend of 6, 472 as of the repricing date. The warrants had been previously issued with exercise prices ranging from .50 to .50. In addition, in September 2003, we issued 631, 882 warrants to a shareholder which had a fair value of 6, 014 and was recorded as a preferential warrant dividend. Fiscal Year 2002 vs. 2001 During 2002, we generated 4, 925 of revenues through sales of titanium dioxide nanoparticles, lithium titanate nanoparticles and other materials. Titanium dioxide nanoparticle sales included , 073 sold to a customer for use in commercial thermal spray applications. Revenues also included , 300 earned under a services agreement entered into with a materials company in September 2002. Under the terms of the agreement, we tested the materials company's mineral concentrates in the production of titanium dioxide pigments using our titanium processing technology. The testing was conducted over a five-month period and generated total revenues of 9, 000 at its completion in early 2003. Also included in revenues in 2002 was , 270 earned from a consulting project involving use of the Altair jig to recover titanium dioxide from pigment processing waste. During 2002, we suffered from a shortage of working capital which forced us to reassess planned expenditures for our development projects. We elected to concentrate our resources on the development of the nanomaterials and titanium dioxide pigment technology and suspend development work on the Tennessee mineral property and jig. As a result of this, expenditures for mineral exploration and development decreased from 0, 777 in 2001 to 8, 977 in 2002. During 2002, our research and development "R&D" ; efforts were directed toward pharmaceuticals, the titanium pigment process, batteries, catalysts, thermal spray coatings and fuel cells. R&D expense increased from 9, 454 in 2001 to 7, 137 in 2002, primarily as a result of increased staff time being devoted to these R&D projects with a resulting decrease in time spent on construction projects and administrative and general activities. Professional services, which consist principally of legal, consulting and audit expenses, increased from 3, 088 in 2001 to 2, 530 in 2002. Consulting expenses increased from 8, 000 in 2001 to 7, 000 in 2002, primarily as a result of our efforts to locate and secure additional financing. Legal fees increased from 7, 000 in 2001 to 5, 000 in 2002, primarily as a result of the preparation of regulatory filings and other documents associated with financing activities and costs associated with patent applications. These increases were partially offset by a decrease in audit expenses of , 000. During 2002, we reduced our general and administrative expenses as much as possible in order to conserve cash. As a result, these expenses decreased by 4, 331 to , 360, 315 in 2002, compared to , 824, 646 in 2001. The major components of general and administrative expenses that decreased in 2002 were: o Investor relations - these expenses decreased by 3, 000 from 6, 000 to , 000 ; due to a significant reduction in investor relations programs. o Rents - Our purchase of the building that we previously rented at 204 Edison Way in Reno, Nevada, and the relocation of staff from rented office space to the purchased building resulted in a reduction of rents expense by , 000 from 4, 000 to 7, 000 ; . o Sample costs - these decreased by , 000 from 3, 000 to 9, 000 ; due to the purchase of raw materials in bulk quantities as opposed to smaller lots, and less labor being required in sample production. 41.